Literature DB >> 2687851

Animal pharmacology of raclopride, a selective dopamine D2 antagonist.

H Hall1, S O Ogren, C Köhler, O Magnusson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2687851     DOI： 10.1007/978-3-642-74430-3_13

Source DB:  PubMed          Journal:  Psychopharmacol Ser        ISSN： 0931-6795


× No keyword cloud information.
  5 in total

Review 1.  Dealing with sadness, madness and hostility. New psychotropic drug remedies for the future.

Authors:  A J Loonen
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 2.  Positron emission tomography in Parkinson's disease: insights into impulsivity.

Authors:  Adam J Stark; Daniel O Claassen
Journal:  Int Rev Psychiatry       Date:  2017-12-05

3.  Nigrostriatal and Mesolimbic D2/3 Receptor Expression in Parkinson's Disease Patients with Compulsive Reward-Driven Behaviors.

Authors:  Adam J Stark; Christopher T Smith; Ya-Chen Lin; Kalen J Petersen; Paula Trujillo; Nelleke C van Wouwe; Hakmook Kang; Manus J Donahue; Robert M Kessler; David H Zald; Daniel O Claassen
Journal:  J Neurosci       Date:  2018-02-26       Impact factor: 6.167

4.  Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.

Authors:  J G Csernansky; J W Newcomer; K Jackson; L Lombrozo; K F Faull; R Zipursky; A Pfefferbaum; W O Faustman
Journal:  Psychopharmacology (Berl)       Date:  1994-11       Impact factor: 4.530

5.  [18F]fallypride characterization of striatal and extrastriatal D2/3 receptors in Parkinson's disease.

Authors:  Adam J Stark; Christopher T Smith; Kalen J Petersen; Paula Trujillo; Nelleke C van Wouwe; Manus J Donahue; Robert M Kessler; Ariel Y Deutch; David H Zald; Daniel O Claassen
Journal:  Neuroimage Clin       Date:  2018-02-10       Impact factor: 4.881
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.